The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands

Michael Schaapveld · Otto Visser · W. J. Louwman · Pax H. B. Willemse · Elisabeth G. E. de Vries · Winette T. A. van der Graaf · Renée Otter · Jan Willem W. Coebergh · Flora E. van Leeuwen

Received: 19 July 2007 / Accepted: 20 July 2007 / Published online: 9 August 2007 © Springer Science+Business Media, LLC 2007

Abstract  Background The impact of age and adjuvant therapy on contralateral breast cancer (CBC) risk and prognostic significance of CBC were evaluated. Patients and Methods In 45,229 surgically treated stage I–IIIA patients diagnosed in the Netherlands between 1989 and 2002 CBC risk was quantified using standardised incidence ratios (SIRs), cumulative incidence and Cox regression analysis, adjusted for competing risks. Results Median follow-up was 5.8 years, in which 624 CBC occurred <6 months after the index cancer (synchronous) and 1,477 thereafter (metachronous). Older age and lobular histology were associated with increased synchronous CBC risk. Standardised incidence ratio (SIR) of CBC was 2.5 (95% confidence interval (95% CI) 2.4–2.7). The SIR of metachronous CBC decreased with index cancer age, from 11.4 (95% CI 8.6–14.8) when <35 to 1.5 (95% CI 1.4–1.7) for ≥60 years. The absolute excess risk of metachronous CBC was 26.8/10,000 person-years. The cumulative incidence increased with 0.4% per year, reaching 5.9% after 15 years. Adjuvant hormonal (Hazard rate ratio (HR) 0.58; 95% CI 0.48–0.69) and chemotherapy (HR 0.73; 95% CI 0.60–0.90) were associated with a markedly decreased CBC risk. A metachronous CBC worsened survival (HR 1.44; 95% CI 1.33–1.56). Conclusion Young breast cancer patients experience high synchronous and metachronous CBC risk. Adjuvant hormonal or chemotherapy considerably reduced the risk of CBC. CBC occurrence adversely affects prognosis, emphasizing the necessity of long-term surveillance directed at early CBC-detection.

Keywords  Adjuvant systemic therapy · Contralateral breast cancer · Prognosis · Radiotherapy

Introduction

Breast cancer is the most common malignancy in women in North America and Western Europe. Contralateral breast cancer (CBC) is the most frequent second cancer reported after primary breast cancer, comprising between 30 and 50% of all second cancers [1–5]. Breast cancer patients appear to have a two- to threefold increased risk of developing CBC. Previous studies observed a constant increase in CBC risk over time, up to a cumulative risk of
5–7% 10 years after diagnosis [6–9]. However, most studies included patients diagnosed and treated more than 15–20 years ago while indications for adjuvant treatment have changed since.

Factors such as family history, young age and lobular histology have been associated with increased CBC risk [6, 8, 10–12]. There is increasing evidence that adjuvant treatment affects CBC risk. A meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) showed that tamoxifen for 2 or 5 years resulted in proportional reductions of the CBC incidence of 26% and 47%, respectively [13]. Recent data suggest that aromatase inhibitors may be even more effective in reducing CBC [14–16]. The EBCTCG meta-analyses showed also a marginally significant 20% decrease in CBC risk after adjuvant chemotherapy [17]. Radiation doses to the contralateral breast are generally fairly low and rather unlikely to confer an increased CBC risk. However, a large case-control study did find an increased radiation-associated risk among long-term breast cancer survivors diagnosed between 1935 and 1982, who received radiotherapy before age 45 [18]. A recent analysis of SEER data also found a slightly increased CBC risk after radiotherapy in patients aged <45 years, surviving longer than 5 years [6].

No recent data are available investigating the effects of current breast cancer therapy on CBC risk among unselected breast cancer patients. The effects of current adjuvant treatment options on CBC occurrence and the impact of CBC on patient survival are important and can provide guidance for follow-up. Therefore we analysed CBC occurrence in a large population-based cohort of Dutch breast cancer patients, diagnosed between 1989 and 2002, evaluating the impact of age and treatment of the index cancer and time since diagnosis on CBC risk. In addition the prognostic significance of CBC was studied.

Methods

Patients

The cohort comprises all surgically treated stage I–IIIA (comprising TNM stages up to and including T3N1M0) primary breast cancer patients diagnosed in the Comprehensive Cancer Centre North (CCCN), Amsterdam (CCCA) and South (CCCS) regions from January 1989 until January 2003. Their cancer registries cover the northwestern and southeastern part of the Netherlands, an area with 7.2 million inhabitants (45% of the Dutch population). The cohort was composed in accordance to privacy regulations of the Netherlands Cancer Registry (NCR).

Data collection

PALGA, the nationwide Dutch network and registry of histo- and cytopathology submits reports of diagnosed malignancies to the Dutch cancer registries. The national hospital databank, which receives discharge diagnoses of all Dutch hospitals, completes case ascertainment. Registry personnel collect data on diagnosis, stage and treatment from the medical records using the registration and coding manual of the NCR. All Dutch patients are treated in public hospitals. Vital status and date of death were established from the patient’s medical record or through linkage with municipal population registries or the national death registry of the Central Bureau for Genealogy (CBG). Date of censoring was set at 12-31-2004.

Stage was based on pathological information or clinical information if pathology data were missing [19, 20]. All primary cancers before or after the index breast cancer were ascertained through a computerised record linkage method. Patients with invasive breast cancer following a non-invasive breast cancer, treated with ablation or amputation, and patients with a previous invasive cancer other than non-melanoma skin cancer were excluded. Any CBC, not classified as a recurrence, was considered a primary CBC. Patients who presented with CBC and distant metastases at diagnosis of this CBC were included. Information on the occurrence of metastases during follow-up was incomplete in the registries and determining whether these metastases were due to the index cancer or due to the CBC was not otherwise possible. To facilitate comparison with international literature non-invasive CBC was excluded as event. Non-invasive CBC comprised about 10% of all CBC and some 5% of the non-invasive CBC was followed by an invasive CBC. Patients who developed a non-invasive CBC, treated with ablation or amputation, were censored at date of diagnosis of this tumour. An invasive CBC diagnosed within 6 months of the index cancer was defined as synchronous, all others as metachronous CBC.

Treatment

The prevailing treatment guidelines during the study period are outlined below. Breast conserving surgery with axillary lymph node dissection was indicated for tumours <4 cm, complemented with radiotherapy to the breast. Alternatively, a modified radical mastectomy was performed. Loco-regional radiotherapy, consisting of parasternal, axillary, infra and supra-clavicular nodal irradiation, was indicated in case of >3 positive axillary nodes or extranodal growth. Irradiation of the parasternal nodes was indicated for node-positive patients with a medially located tumour. Pre-menopausal node-positive patients received...
adjuvant chemotherapy, generally consisting of cyclophosphamide, methotrexate and 5-fluorouracil. Anthracycline-based chemotherapy was increasingly used for high-risk patients since the mid-1990s. Until 1998 post-menopausal node-positive patients received 2 years tamoxifen. Since 1998, adjuvant systemic therapy was also administered to node-negative patients with less favourable tumour characteristics (intermediate or poorly differentiated tumours ≥ 2 cm). Furthermore, since 1998 all hormone-receptor-positive node-positive and unfavourable node-negative patients were to receive 5-years tamoxifen, irrespective of menopausal status. Inoperable and locally advanced cancers received chemotherapy, hormonal therapy and/or radiotherapy.

Statistical analysis

CBC risk was quantified using various risk measures. The standardised incidence ratio (SIR) compares the observed with expected numbers of CBC based on age- and calendar-year specific breast cancer incidence rates for the Dutch female population. The 1989, 1990, 1992, 1994, 1996, 1998, 2000 and 2002 incidence rates were derived from the NCR and used to compute expected CBC numbers. Time at risk started at the date of index cancer diagnosis for synchronous CBC and 6 months thereafter for metachronous CBC and ended at the date of CBC diagnosis, the date of death or the date of last linkage with the municipal population registry or CBG. No information on prophylactic contralateral mastectomies was available. The CIs for the SIRs were calculated assuming a Poisson distribution for the observed number of CBC. SIRs were computed by age at diagnosis (<35, 35–39, 40–49, 50–59, 60–69, 70–79 and 80+), stage (T1N0, T2N0, T3N0, T1N1, T2N1, T3N1), treatment (adjuvant chemotherapy, hormonal therapy or both combined (with or without radiotherapy), adjuvant radiotherapy and surgery only) and follow-up interval (<6 months, 6 months–4 years, 5–9 years and 10–14 years). Adjusted SIRs for metachronous CBC by age, stage, treatment and follow-up period were estimated with Poisson regression analysis. Poisson model fit was evaluated using residual-based graphical methods and goodness-of-fit test statistics. All reported P-values are two sided, the statistical significance level was set at a P-value <0.05.

Results

The cohort comprised 45,229 women with breast cancer. The median follow-up was 5.8 years (Inter Quartile Range 3.4–9.1 years) and 12,584 patients died during follow-up. The patients accumulated 295,097 person-years, 83,396 person-years for the 5–9 year period and 21,379 person-years for the period ≥ 10 years after index cancer diagnosis. Only 0.1% of the patients were followed less than 6 months. In total, 2,101 patients developed a CBC, of which 624 were synchronous and 1,477 metachronous.

Risk of synchronous CBC

The frequency of synchronous CBC was 1.4% and increased with age (P < 0.001, Table 1). A very high SIR of synchronous CBC was observed for patients <35 years. The SIR was markedly lower for patients aged 35–70 years and increased again among those aged ≥ 70. A logistic regression analysis showed an increase in risk of synchronous CBC increased with older age (Odds ratio (OR) for each 10-year increase 1.36; 95% CI 1.28–1.45), presence of lymph node metastasis (OR 1.27; 95% CI 1.07–1.49) and for lobular index cancer histology (OR 1.56; 95% CI 1.28–1.91).

Relative risk of metachronous CBC

The SIR was 2.5 (95% CI 2.4–2.7) for all and 1.9 (95% CI 1.8–2.1) for metachronous CBC. In univariate Poisson analysis the SIR of metachronous CBC decreased with age at index cancer diagnosis; the SIR was 11.4 (95% CI 8.6–14.8) for women <35 years and 1.5 (95% CI 1.4–1.7) for women aged ≥ 60 years, respectively (P < 0.001, Table 1).
Table 1 Number of patients (No), observed number (O), frequency (%) and standardised incidence ratios (SIR) of synchronous CBC and observed number, 5- 10- and 15-year cumulative incidence (CR), SIRs and absolute excess risk (AER) of metachronous CBC according to age, stage and treatment of the index cancer

|                | Synchronous CBC | Metachronous CBC |                |                |
|----------------|-----------------|------------------|----------------|----------------|
|                | O | % | SIR   | 95% CI | O   | SIR | 95% CI | AER  | 5-year CR (%) | 10-year CR (%) | 15-year CR (%) |
| All patients   | 45,229 | 624 | 1.4 | 10.4 | 9.6–11.3 | 1,477 | 1.9 | 1.8–2.1 | 26.8 | 2.1 | 4.2 | 5.9 |
| Age            |                |                  |                |                  |
| <35            | 1,198 | 13 | 1.1 | 81.7 | 43.5–139.8 | 58 | 11.4 | 8.6–14.8 | 72.8 | 2.9 | 6.1 | 7.4 |
| 35–39          | 1,999 | 7 | 0.4 | 9.7 | 3.8–20.9 | 85 | 4.9 | 3.9–6.1 | 53.8 | 2.9 | 4.6 | 7.0 |
| 40–49          | 9,121 | 78 | 0.9 | 9.7 | 7.6–12.1 | 343 | 2.4 | 2.1–2.7 | 34.4 | 2.4 | 4.5 | 6.9 |
| 50–59          | 11,179 | 129 | 1.2 | 8.6 | 7.1–10.2 | 346 | 1.8 | 1.5–2.0 | 22.5 | 1.9 | 4.3 | 6.1 |
| 60–69          | 10,386 | 140 | 1.4 | 8.5 | 7.1–10.0 | 334 | 1.5 | 1.3–1.8 | 18.3 | 1.8 | 4.2 | 6.1 |
| 70–79          | 8,056 | 159 | 2.0 | 11.6 | 9.8–13.6 | 255 | 1.7 | 1.5–2.0 | 25.3 | 2.1 | 4.0 | 5.3 |
| 80+            | 3,290 | 98 | 3.0 | 17.2 | 13.9–20.9 | 56 | 1.2 | 0.9–1.6 | 7.8 | 1.4 | 2.0 | 2.3 |
| Stage (TNM)    |                |                  |                |                  |
| T1 N0          | 18,474 | 225 | 1.2 | 9.0 | 7.8–10.3 | 704 | 2.1 | 1.9–2.3 | 32.0 | 2.4 | 4.9 | 7.2 |
| T2 N0          | 8,862 | 130 | 1.5 | 10.6 | 8.8–12.7 | 325 | 2.0 | 1.8–2.3 | 31.5 | 2.3 | 4.4 | 6.2 |
| T3 N0          | 439 | 5 | 1.1 | 8.4 | 2.7–19.6 | 13 | 1.8 | 0.9–3.1 | 24.4 | 2.1 | 2.8 | 4.3 |
| T1 N1          | 7,160 | 99 | 1.4 | 10.9 | 8.8–13.4 | 162 | 1.4 | 1.1–1.7 | 10.9 | 1.4 | 3.2 | 4.8 |
| T2 N1          | 9,100 | 138 | 1.5 | 11.9 | 9.9–14.1 | 220 | 1.6 | 1.4–1.9 | 17.9 | 1.5 | 3.2 | 3.9 |
| T3 N1          | 1,194 | 27 | 2.3 | 19.6 | 12.9–28.6 | 53 | 3.7 | 2.8–4.9 | 73.3 | 3.4 | 5.2 | 6.8 |
| Adjuvant treatment |            |                  |                |                  |
| CT             | 6,121 | 59 | 1.0 | 10.7 | 8.1–13.9 | 177 | 2.3 | 1.9–2.7 | 29.1 | 2.0 | 3.9 | 5.4 |
| HT             | 11,698 | 265 | 2.3 | 12.9–16.6 | 233 | 1.1 | 0.9–1.3 | 4.3 | 1.3 | 2.7 | 3.3 |
| CT and HT      | 2,564 | 38 | 1.5 | 14.7 | 10.3–20.2 | 34 | 1.6 | 1.1–2.3 | 14.3 | 1.2 | 4.5 | 6.5 |
| RT (without CT/HT) | 13,044 | 91 | 0.7 | 5.3 | 4.2–6.6 | 527 | 2.2 | 2.0–2.4 | 34.4 | 2.4 | 4.9 | 7.5 |
| No adjuvant treatment | 11,802 | 171 | 1.5 | 10.3 | 8.8–12.0 | 506 | 2.2 | 2.0–2.5 | 37.5 | 2.6 | 5.0 | 6.8 |

- **a** Absolute excess risk is expressed per 10,000 person years
- **b** CT = chemotherapy, HT = hormonal therapy, RT = radiotherapy

Fig. 1 Standardised incidence ratios (SIRs) and 95% confidence intervals for metachronous contralateral breast cancer, according to age at diagnosis and time since diagnosis of the index cancer.
The SIR increased slightly with longer follow-up, from 1.8 after 0.5–4 years to 2.0 after 5–9 years and 2.1 after 10–14 years of follow-up ($P = 0.081$). However, as Fig. 1 shows the age-specific SIRs for metachronous CBC actually decreased with follow-up time for patients younger than 40 years and increased only for older patients (interaction term age*follow-up period $P < 0.001$).

Crude SIRs of metachronous CBC were 1.1 (95% CI 0.9–1.3) following adjuvant hormonal therapy, 2.3 (95% CI 1.9–2.7) following adjuvant chemotherapy and 2.2 (95% CI 2.0–2.4) for patients not receiving hormonal or chemotherapy. Adjusted for age at index cancer diagnosis the SIRs for both hormonal (SIR 0.9; 95% CI 0.6–1.2) and chemotherapy (SIR 1.1; 95% CI 0.8–1.6) were in line with expected CBC numbers based on Dutch female population incidence rates, whereas the SIRs following surgery with/without radiotherapy remained elevated (SIR 1.5; 95% CI 1.1–2.1).

Excess risk of metachronous CBC

The AER of developing a metachronous CBC was 26.8 per 10,000 woman-years (95% CI 23.2–30.4). The AER decreased with age at index cancer diagnosis, from 72.7 (95% CI 51.3–94.2) to 7.8 (95% CI 7.7–23.4) per 10,000 person-years for women < 35 years and ≥ 80 years, respectively. Adjuvant hormonal therapy was associated with a very low AER of 4.3 (95% CI −2.3–11.0) per 10,000 person-years.

Cumulative incidence of metachronous CBC

The cumulative incidence for metachronous CBC was 2.1% (95% CI 1.9–2.3%) at 5 years, 4.2% (95% CI 3.9–4.5%) at 10 years and 5.9% (95% CI 5.5–6.4%) at 15 years of follow-up. The cumulative incidence increased at an average rate of 0.4%/year. The highest cumulative incidence was observed for patients younger than 40 years (Fig. 2). The cumulative incidence increased with tumour size when positive lymph node metastases were present (Table 1). For patients receiving surgery only the 10-year cumulative metachronous CBC incidence was 5.0% (95% CI 4.5–5.5%).

Hormonal therapy (HR 0.57, $P < 0.001$) and chemotherapy (HR 0.79, $P = 0.003$) were associated with a lower cumulative incidence of metachronous CBC compared to patients not receiving adjuvant systemic therapy in univariate CPH, adjusted for competing risks. Combined adjuvant hormonal and chemotherapy was associated with a decreased risk of CBC (HR 0.58, $P = 0.002$), similar in magnitude to that for adjuvant hormonal therapy only.

In a multivariate CPH, treatment with adjuvant hormonal (HR 0.58; 95% CI 0.48–0.69) or chemotherapy (HR 0.73; 95% CI 0.60–0.90), with or without radiotherapy, were associated with a reduced CBC risk, compared to no adjuvant systemic therapy (Table 2). The HR of a metachronous CBC increased with tumour size, but decreased with age at index cancer diagnosis. The histology of the index cancer was not associated with metachronous CBC risk. The HR of CBC did not differ between patients treated with surgery and radiotherapy or surgery only. However, in a multivariate CPH stratified for age, radiotherapy appeared associated with a, albeit non-significantly, increased CBC risk (HR 1.37 $P = 0.111$, Table 2A) after adjusting for adjuvant hormonal and chemotherapy, age and stage. When the analysis was restricted to 5-year survivors, hormonal treatment was still associated with a decreased CBC risk (HR 0.65; 95% CI 0.48–0.87, Table 2B).

Association of metachronous CBC with survival

Diagnosis of a CBC was associated with worse survival compared to patients without CBC. The HR of death
Table 2  Multivariate Cox regression analysis of risk factors for the occurrence of metachronous contralateral breast cancer during follow-up, (A) by age group (adjusted for competing risks) (B) by age groups for 5-year survivors (adjusted for competing risks)

| Risk factor | Age | HR   | 95% CI | P-value | HR   | 95% CI | P-value | HR   | 95% CI | P-value | HR   | 95% CI | P-value |
|-------------|-----|------|--------|---------|------|--------|---------|------|--------|---------|------|--------|---------|
| Tumour size (cm) |       |      |        |         |      |        |         |      |        |         |      |        |         |
| 0–2         | <40 | 1.00 | 1.00   | <0.001  | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | <0.001 |
| >2–5        | 50–69 | 0.89 | 0.61–1.30 | 1.03 | 0.81–1.30 | 1.07 | 0.97–1.20 | 1.04 | 0.88–1.24 |
| >5          | ≥70 | 2.31 | 1.32–4.34 | 0.27 | 0.06–1.08 | 1.81 | 1.40–2.34 | 1.04 | 0.88–1.24 |
| Lymph nodes |       |      |        |         |      |        |         |      |        |         |      |        |         |
| Node-negative | 0–2 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | <0.001 |
| Node-positive | >2–5 | 0.89 | 0.61–1.30 | 1.03 | 0.81–1.30 | 1.07 | 0.97–1.20 | 1.04 | 0.88–1.24 |
| Age         |       |      |        |         |      |        |         |      |        |         |      |        |         |
| Agea        |       |      |        |         |      |        |         |      |        |         |      |        |         |
| Hormonal therapy | 0–2 | 0.80 | 0.50–1.25 | 0.95 | 0.87–1.04 | 0.79 | 0.61–1.02 | 0.64 | 0.51–0.81 |
| Chemotherapy | >2–5 | 0.35 | 0.14–0.88 | 0.71 | 0.56–0.90 | 0.98 | 0.78–1.24 | 0.003 | 0.73–0.90 |
| Radiotherapy | ≥70 | 1.37 | 0.93–2.01 | 0.92 | 0.80–1.05 | 0.91 | 0.71–1.17 | 0.477 | 0.73–0.90 |
| (B) Tumour size (cm) |       |      |        |         |      |        |         |      |        |         |      |        |         |
| 0–2         | <40 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | <0.001 |
| >2–5        | 50–69 | 0.70 | 0.37–1.29 | 1.07 | 0.87–1.31 | 1.12 | 0.76–1.63 | 1.04 | 0.87–1.23 |
| >5          | ≥70 | 1.58 | 1.54–4.60 | 1.46 | 0.85–1.48 | 1.25 | 0.78–2.00 | 0.448 | 0.25–0.78 |
| Lymph nodes | Node-negative | 0.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | <0.001 |
| Node-positive | 0–2 | 0.70 | 0.37–1.29 | 1.07 | 0.87–1.31 | 1.12 | 0.76–1.63 | 1.04 | 0.87–1.23 |
| Ageb        | >2–5 | 0.70 | 0.37–1.29 | 1.07 | 0.87–1.31 | 1.12 | 0.76–1.63 | 1.04 | 0.87–1.23 |
| Hormonal therapy | ≥70 | 0.35 | 0.14–0.88 | 0.71 | 0.56–0.90 | 0.98 | 0.78–1.24 | 0.003 | 0.73–0.90 |
| Chemotherapy | Radiotherapy | 1.37 | 0.93–2.01 | 0.92 | 0.80–1.05 | 0.91 | 0.71–1.17 | 0.477 | 0.73–0.90 |

HR = hazard ratio; 95% CI = 95% confidence interval

a age, centred to the mean, continuous, every 10-year increase
b age, centred to the mean, continuous, every 10-year increase

HR = hazard ratio; 95% CI = 95% confidence interval
Table 3 Multivariate Cox regression analysis of overall survival, with CBC as a time-dependent covariate

| Risk factor | HR  | 95% CI | P-value |
|-------------|-----|--------|---------|
| Stage of CBC (CBC yes versus no; time-dependent covariate) |     |        |         |
| Stage I     | 0.99| 0.86–1.15 | 0.936 |
| Stage II    | 1.32| 1.13–1.54 | <0.001|
| Stage III/IV| 4.91| 3.82–6.31 | <0.001|
| Stage unknown | 1.11| 0.69–1.77 | 0.661 |

Adjusted for age and stage at index cancer diagnosis, both fitted as time-varying covariates

HR = hazard ratio; 95% CI = 95% confidence interval

following CBC diagnosis was 1.44 (95% CI 1.33–1.56) compared to patients without CBC. Table 3 shows that the HR of death, adjusted for age and stage of the index cancer, differed according to CBC stage. While a stage I CBC did not increase the HR of death, stage II CBC increased the risk of death 1.3 fold.

Discussion

In this large population-based cohort comprising over 45,000 breast cancer patients we observed a 2.5-fold increased CBC risk. Assuming independence, the risk expressed in breast-years would be twice as high as in breast cancer survivors only one breast is at risk for CBC and the reference incidence rates concern cancer in any of two breasts. The cumulative incidence of metachronous CBC increased by 0.4% annually and did not level off even after 10 years of follow-up. Furthermore, a metachronous CBC in stage II or higher was associated with worse survival. Very high SIRs of CBC were observed for the youngest patients. Adjuvant hormonal and chemotherapy were associated with a 42% and 27% risk reduction of metachronous CBC, respectively. Adjusted for age, SIRs were not elevated in patients receiving adjuvant systemic therapy.

In our study 1.4% of the patients were diagnosed with synchronous CBC. Treatment does not likely affect the risk of synchronous CBC, therefore this figure should be directly comparable between studies. The frequency reported in the literature varies between less than 1 and 3%, largely depending on the time window chosen to define synchronous CBC [9, 24, 25]. Our definition of synchronous CBC, diagnosis within 6 months of the index cancer, reflects the average time window in the literature. Differences in the diagnostic work-up, especially more frequent use of bilateral mammography, can also affect the frequency of synchronous CBC and may hamper comparison between studies [26, 27]. Lobular histology was also found associated with synchronous CBC occurrence, confirming earlier findings [8–10].

Several studies have reported a decrease in the risk of metachronous CBC with older age [6, 9, 11]. The very high SIRs of both synchronous and metachronous CBC for the youngest patients in our study were remarkable, with a more than 11-fold increased risk of metachronous and a more than 80-fold increased risk of synchronous CBC in patients aged <35. This was accompanied by the highest AERs, showing that these high SIRs cannot just be explained by a lower background incidence. Early onset breast cancer is a well recognized feature of hereditary breast cancer and mutations of the BRCA1 or BRCA2 genes strongly predisposes for CBC development [28–30]. Magnetic resonance imaging (MRI) may have a place in regular surveillance of these women [31]. Based on the results of our study all young women with breast cancer may be clear candidates for regular MRI screening directed at early CBC detection.

The 10-year cumulative incidence of metachronous CBC in our study (4.0%) was relatively low compared to earlier studies [6–9]. This could be related to the increasing application of adjuvant systemic therapy over the last decades. In a study in patients diagnosed between 1975 and 1995 about 12.5% received hormonal therapy against about 32% in our study [9]. In our study hormonal therapy was associated with a reduction of metachronous CBC risk by 42%. The reduction is comparable to the reduction seen in the EBCTCG meta-analysis and might be even higher than could be expected based on the EBCTCG meta-analysis, especially considering the fact that most of our patients received tamoxifen for 2 years only [13]. Our finding was also in line with the reduction of invasive breast cancer incidence observed in the NSABP tamoxifen prevention trial [32]. Aromatase inhibitors may even further reduce CBC risk [14–16]. Ongoing trials will determine the precise place of aromatase inhibitors, in terms of efficacy and safety, for the adjuvant treatment of breast cancer. CBC prevention will be an important endpoint in these studies. Interestingly, we also observed that adjuvant chemotherapy was associated with a 27% reduction of CBC. Although less than after hormonal therapy, this risk reduction was comparable to that seen in the polychemotherapy EBCTCG meta-analysis [17].

In our study relatively few patients received combined adjuvant systemic therapy and most were treated after 1997. Although our data do not allow firm conclusions about the effect of combined adjuvant systemic therapy, with a 42% proportional reduction of CBC occurrence combined systemic therapy appeared to be associated with a risk reduction similar to hormonal therapy alone.

Several studies have shown, that depending on the radiation technique used, the contralateral breast receives 1–13% of the applied dose to the treated breast, with the highest estimates reflecting scatter radiation to the medial
part of the contralateral breast [33–35]. These doses are well within the tumourigenic range. Studies in atomic bomb survivors have shown decreasing radiation induced breast cancer risks with advancing age and no increased risk when irradiated over the age of 40 years [36].

Radiotherapy was not associated with a significantly increased CBC risk in our study. However, adjuvant systemic therapy is currently given to a high proportion of patients aged <40 years (56% in our study) and a protective effect of systemic therapy may well balance any increased risk caused by irradiation. The SEER data revealed an increased CBC risk associated with radiotherapy for patients surviving ≥5 years, with a 1.3 fold risk increase in patients aged <45 years at index cancer diagnosis [6]. When restricted to CBCs diagnosed ≥5 years after the index cancer, radiotherapy before the age of 40 years was not associated with CBC risk, although the risk estimate (HR 1.4) was comparable with SEER data. Possibly longer follow-up of our cohort may reveal an association between radiotherapy and CBC risk.

Our study showed that metachronous CBC stage II or higher was associated with worsened survival. Previously, patients who developed CBC were found to be at increased risk of disease recurrence and death [6, 8, 24]. An issue which may affect all studies of CBC risk is the difficulty in distinguishing CBC from metastases of the index cancer. However, several recent studies, which attempted to differentiate CBC between metastasis and second primary cancer using molecular-genetic techniques, did conclude that most localized metachronous CBC were distinct entities [37–39]. Most patients with metachronous CBC in our study were without evidence of distant metastases. However, metachronous CBC with distant metastases were not excluded and consequently CBC risk may have been slightly overestimated.

The strengths of our study derive from its population-based character. The cohort includes a large number of patients with a nearly complete follow-up for vital status and, based on cancer registry data, the follow-up for CBC is virtually complete. Therefore this study provides a reliable estimate of the CBC risk and illustrates the potential of adjuvant treatment for CBC prevention.

Our study does harbour some limitations. Information on treatment for tumour recurrence was not recorded by the cancer registries. Furthermore, some underestimation of especially hormonal treatment may have occurred, as registration may sometimes have taken place before primary treatment was completed, and may have resulted in some underestimation of the effect of adjuvant treatment on CBC risk. However, studies using cancer registry data for evaluation of breast cancer treatment guideline adherence in the Netherlands showed generally good agreement between registry treatment data and suggested treatment by guidelines [40–42]. Longer follow-up is required to determine whether the prophylactic effect of tamoxifen on CBC occurrence will persist over time. Also, the effect of more prolonged tamoxifen (5 years instead of 2 years) and the effects of combined chemotherapy and hormonal therapy on CBC risk need further investigation.

As there is no evidence of a decreasing risk over time and metachronous CBC negatively affects patient's survival, regular long-term screening of the contralateral breast remains necessary. A combined approach with MRI and mammography appears most advisable for the youngest patient group. With broadening indications for adjuvant systemic treatment and new hormonal agents the CBC incidence may further decrease in the future.

References

1. Harvey EB, Brinton LA (1985) Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr 68:99–112
2. Brenner H, Siegle S, Stegmaier C et al (1993) Second primary neoplasms following breast cancer in Saarland, Germany 1968–1987. Eur J Cancer 29a:1410–1414
3. Volk N, Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8:764–770
4. Evans HS, Lewis CM, Robinson D et al (2001) Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 84:435–440
5. Soerjomataram I, Louwman WJ, de Vries E et al (2005) Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972–2001. Breast Cancer Res Treat 93:91–95
6. Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56:1038–1045
7. Healey EA, Cook EF, Orav EJ et al (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11:1545–1552
8. Broet P, de la Rochefordiere A, Scholl SM et al (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13:1578–1583
9. Kollias J, Ellis IO, Elston CW, Blamey RW (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25:1117–1124
10. Bernstein JL, Thompson WD, Risch N, Holford TR (1992) Risk factors predicting the incidence of second primary cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925–936
11. Kollias J, Ellis IO, Elston CW, Blamey RW (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25:584–589
12. Vaittinen P, Hemminki K (2000) Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 88:998–1002
13. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467
14. ATAC Trialist’s Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139
